BACKGROUND: Ewing sarcoma survivors (ESSs) are at increased risk for treatment-related complications. The incidence of treatment-related morbidity and late mortality with aging is unknown. METHODS: This study reports survival probabilities, estimated with the Kaplan-Meier method, and the cumulative incidence of cause-specific mortality and chronic conditions among ESSs in the Childhood Cancer Survivor Study who were treated between 1970 and 1986. Piecewise exponential models were used to estimate relative rates (RRs) and 95% confidence intervals (CIs) for these outcomes. Chronic conditions were graded with the Common Terminology Criteria for Adverse Events (version 4.03). RESULTS: Among 404 5-year ESSs (median age at last follow-up, 34.8 years; range, 9.1-54.8 years), the 35-year survival rate was 70% (95% CI, 66%-74%). Late recurrence (cumulative incidence at 35 years, 15.1%) was the most common cause of death, and it was followed by treatment-related causes (11.2%). There were 53 patients with subsequent neoplasms (SNs; cumulative incidence at 35 years, 24.0%), and 38 were malignant (14.3% at 35 years). The standardized incidence ratios were 377.1 (95% CI, 172.1-715.9) for osteosarcoma, 28.9 (95% CI, 3.2-104.2) for acute myeloid leukemia, 14.9 (95% CI, 7.9-25.5) for breast cancer, and 13.1 (95% CI, 4.8-28.5) for thyroid cancer. Rates of chronic conditions were highest for musculoskeletal (RR, 18.1; 95% CI, 12.8-25.7) and cardiac complications (RR, 1.8; 95% CI, 1.4-2.3). Thirty-five years after the diagnosis, the cumulative incidences of any chronic conditions and 2 or more chronic conditions were 84.6% (95% CI, 80.4%-88.8%) and 73.8% (95% CI, 67.8%-79.9%), respectively. CONCLUSIONS: With extended follow-up, ESSs' risk for late mortality and SNs does not plateau. Treatment-related chronic conditions develop years after therapy, and this supports the need for lifelong follow-up.
INTRODUCTION
The use of multimodality therapy for children and adolescents with Ewing sarcoma has incrementally improved the 5-year event-free survival rate to 60% to 70%. [1] [2] [3] [4] [5] However, treatment requires the use of high doses of chemotherapy, including alkylating agents and anthracyclines, and aggressive local control with surgery and/or high-dose radiotherapy. Though effective, these strategies place survivors at risk for long-term medical complications, including anthracyclineinduced cardiomyopathy 6, 7 and subsequent neoplasms (SNs). [8] [9] [10] [11] As a result, survivors are at increased risk for late mortality (>5 years after the diagnosis) 12 as well as organ toxicities 13 and chronic conditions 14 due to exposure to chemotherapy and radiation early in life.
Initial estimates of late mortality, SNs, and chronic conditions among Ewing sarcoma survivors (ESSs) in the Childhood Cancer Survivor Study (CCSS) were previously reported with data from the baseline questionnaire administered from 1994 through 1996 when the mean age of survivors was 26.3 years (range, 9-45 years). 15 Since then, the CCSS has followed this population through serial questionnaires. Because the risk for SNs (particularly second solid tumors) 8, 11, 16, 17 and other chronic conditions increases over time among survivors, 14 it is important to identify health complications specific to aging ESSs to inform survivorship care.
This report updates cumulative incidence rates for SNs, late mortality, and chronic conditions in 5-year survivors of childhood Ewing sarcoma. We further evaluated musculoskeletal complications by including those related to surgical resection because functional outcomes are influenced by the surgical procedure. 18 We hypothesized that rates of adverse outcomes would increase over time, be greater among survivors versus siblings and population norms, and be associated with a greater intensity of the original therapy.
MATERIALS AND METHODS

Patient Population
The CCSS is a retrospective cohort with longitudinal follow-up of children (<21 years old) who were diagnosed with cancer at 1 of 26 participating institutions between January 1, 1970 and December 31, 1986 and survived at least 5 years. 19, 20 The study protocol was reviewed and approved by institutional review boards at each institution. Informed consent was obtained from participants. Participants completed a baseline questionnaire and 2 subsequent questionnaires that captured major health events (https://ccss.stjude.org/). To provide a comparison population, from a random sample of 50% of survivors, 1 full sibling closest in age was recruited. Siblings received questionnaires identical to those received by survivors except that questions specific to cancer treatment were excluded.
For this report, ESSs eligible for participation in the CCSS (n 5 566) were included in mortality analyses, and 404 completed the baseline questionnaire (1994) (1995) (1996) and were included in the chronic condition and SN analyses. Among the 404 Ewing survivors who completed the baseline questionnaire, 364 completed the follow-up questionnaire in 2000, 238 completed the follow-up questionnaire in 2003, and 202 completed the follow-up questionnaire in 2007. We report information up until the last questionnaire for each survivor. A flow diagram detailing these numbers is provided in Supporting Figure 1 (see online supporting information). Only those consenting to medical-record abstraction were included in analyses that used treatment data.
Cancer Treatment Information
Information about the cancer diagnosis and treatment was abstracted and included cumulative chemotherapy dose, radiation, and surgery data. 21 Radiation records were centrally coded by the CCSS Radiation Physics Center for the estimation of tissue-specific dosimetry. 22 For these analyses, we included the following as independent variables in multivariate models: age at diagnosis, localcontrol modality with surgery (amputation, limb-sparing surgery, thoracotomy, and abdominal surgery), radiotherapy (limb, abdomen, and chest), and chemotherapy exposures (anthracyclines, alkylating agents, and epipodophyllotoxins and their doses).
Outcome Variables
Cause of death
Patients eligible for participation were included in a National Death Index search through 2013. 23 For deaths that predated the National Death Index (ie, those from 1975 to 1978), death certificates from states where the deaths had occurred were requested. Deaths were grouped into 3 mutually exclusive categories with International Classification of Diseases, Ninth Revision (ICD-9) coding and International Classification of Diseases, Tenth Revision (ICD-10) coding: 1) recurrence/progression of the primary cancer; 2) external causes, including accidents, suicides, poisonings, and other external causes (ICD-9, 800-999; ICD-10; V00-V99, Y00-Y89, X00-X99, and W00-W99); and 3) nonrecurrence, nonexternal causes, including SNs (ICD-9, 140-239; ICD-10, C00-C97 and D10-D36), cardiac causes (ICD-9, 390-398, 402, 404, and 410-429; ICD-10, I00-I02, I05-I09, I11, I13, I14, I20-I28, and I30-I52), pulmonary causes (ICD-9, 460-519; ICD-10, J00-J99), and all other causes.
SNs
SNs, occurring 5 or more years after the initial diagnosis, 17 included new neoplasms (malignant and benign) but did not include recurrences of the primary childhood malignancy. Cases were reported by participants and were confirmed by a pathology report or, when that was not available, a death certificate or other medical records. Second malignant neoplasms (SMNs) were defined as those diagnoses included in the US Surveillance, Epidemiology, and End Results registry and did not include nonmelanoma skin cancers or benign meningiomas.
Chronic conditions
Chronic conditions were determined with previous methods, 14 with grades assigned to each event according to the Common Terminology Criteria for Adverse Events Original Article (version 4.03): grade 1 (mild), grade 2 (moderate), grade 3 (severe), grade 4 (life-threatening or disabling), or grade 5 (fatal). In addition to condition severity, the presence of multiple conditions, the specific type of condition, and the interval between the cancer diagnosis and the condition's onset were assessed.
Statistical Analysis
Descriptive statistics were used to characterize the study population. Survival probabilities were estimated with the Kaplan-Meier product-limit method, and cause-specific mortality was estimated with the cumulative incidence method, with other causes of death treated as competing risks. The follow-up for death started at cohort entry (5 years after the diagnosis) and ended at the date of death or censoring (December 31, 2007), whichever was earlier.
Standardized mortality ratios (SMRs) for overall and cause-specific mortality were computed by the division of the observed deaths among survivors by expected deaths from age-, sex-, and calendar year-specific US mortality data. 24 For SMRs, 95% confidence intervals (CIs) assumed a Poisson distribution for the observed number of deaths. For survivors with treatment information, the effects of exposures on mortality were assessed with piecewise exponential models adjusted for sex, race/ethnicity, age at diagnosis, treatment era, and attained age.
The cumulative incidence of SNs was estimated with death as a competing risk. 24 Neoplasms that occurred before cohort entry were considered prevalent at cohort entry in cumulative incidence curves. Standardized incidence ratios (SIRs) of overall and specific types of SMNs were calculated in the same manner as SMRs, with age-, sex-, and calendar year-specific incidence rates from the Surveillance, Epidemiology, and End Results registry used for reference.
The cumulative incidence of chronic conditions was estimated with death, late recurrence, and SMNs after 5 years as competing risks; it was stratified by radiation exposure. Rates of chronic conditions with an onset after cohort entry were estimated among survivors and were compared with rates among siblings with piecewise exponential models adjusted for age, sex, and race/ethnicity. We also evaluated treatment exposures associated with chronic conditions among survivors.
RESULTS
The characteristics of the 404 ESSs and 4022 siblings who completed the baseline questionnaire are described in Table 1. Compared with siblings, survivors were more commonly male and white. The mean age at last follow-up was 33.8 years for survivors (interquartile range, 26.1-41.7 years) and 34.3 years for siblings (interquartile range, 26.7-41.7 years). The most common primary tumor site was a lower extremity, which was followed by an upper extremity and the pelvis. Most survivors received chemotherapy and radiotherapy (67.8%) with or without surgery. The most common radiation site was an extremity, which was followed by the chest and abdomen. As expected, 96.9% of the patients received alkylating agents, and 85.2% received anthracyclines.
Survival and Late Mortality
Among the 566 eligible participants with Ewing sarcoma, there were 169 deaths. The rate of survival 35 years after the diagnosis, conditioned on 5-year survival, for all eligible ESSs was 70.4% (Supporting Fig. 2 [see online supporting information]). The cumulative incidence of death due to recurrent disease was 15.2% 35 years after the diagnosis, and this was followed by nonrecurrence/nonexternal causes (11.2%) and external causes (2.0%; Supporting Fig. 3 [see online supporting information]). The corresponding SMRs were as follows: 8.5 for all (95% CI, 7.3-9.9); 1.1 for external causes (95% CI, 0.5-2.1); and 5.8 for nonrecurrence/nonexternal causes (95% CI, 4.5-7.4), including SNs (7.1; 95% CI, 4.5-10.7), cardiac causes (6.4; 95% CI, 3.6-10.6), and pulmonary causes (3.3; 95% CI, 0.4-12.0). Host and treatment-related risk factors for mortality among survivors are shown in Table 2 . An older age at diagnosis and female sex were associated with higher mortality. The only treatment-related risk factors associated with mortality were exposure to radiation and anthracyclines.
SNs
Among the 53 ESSs with SNs, 38 had malignancies (SMNs). The cumulative incidence of SMNs was 14.3% at 35 years from diagnosis ( Fig. 1) with an overall SIR of 7.8 (95% CI, 5.6-10.6). As shown in Table 3 , breast cancer was the most frequent SMN, and SIRs were highest for osteosarcoma, acute myeloid leukemia, breast cancer, and thyroid cancer. Nearly all survivors who developed SMNs were previously exposed to alkylating agents, anthracyclines, and radiotherapy. The only treatment exposure associated with the risk of SMN was chest radiotherapy.
Chronic Conditions
Twenty-five years after the diagnosis, the cumulative incidences of any grade 1 to 5 chronic condition and 2 or more grade 1 to 5 chronic conditions were 80.0% (95% CI, 75.8%-84.1%) and 61.8% (95% CI, 56.7%-66.8%), respectively (Supporting Fig. 4A ,B [see online supporting information]). Thirty-five years after the diagnosis, the corresponding cumulative incidences were 84.6% (95% CI, 80.4%-88.8%) and 73.8% (95% CI, 67.8%-79.9%), respectively. The frequency of events and relative rates (RRs) in comparison with siblings were highest for musculoskeletal and cardiac complications (Table 4) . Survivors were significantly more likely than siblings to undergo an amputation, a leg-lengthening procedure, joint replacement, or scoliosis surgery 5 or more years after the diagnosis. Similarly, they were at increased risk for congestive heart failure, serious arrhythmias, and myocardial infarction. The musculoskeletal events occurring before 5 years were counted as prevalence in Supporting Figure 5 (see online supporting information). Figure 2 illustrates the cumulative incidence of musculoskeletal and cardiac complications and demonstrates that although most musculoskeletal complications occurred in the first 10 years of follow-up, new-onset musculoskeletal complications were possible decades after treatment had ended. In contrast, cardiac complications were relatively uncommon in the first 10 years, began to increase, and did not appear to plateau even at 30 years of follow-up. Radiation exposure was associated with both musculoskeletal and cardiac complications (Table 5) . We evaluated the impact of radiation therapy on each musculoskeletal condition with separate regression analyses. RRs and 95% CIs for each of the chronic musculoskeletal conditions by radiation exposure are shown in Supporting Table 1 (see online supporting information). Although statistical significance could not be achieved because of the small number of events for each condition, radiation exposure showed a positive association with all the musculoskeletal conditions.
DISCUSSION
This study provides longitudinal follow-up on health outcomes among aging ESSs, nearly 80% of whom were 20 or more years from their diagnosis. Our findings indicate that increases in both late mortality and SMNs do not plateau and that chronic conditions continue to develop years after therapy, particularly among those exposed to radiation therapy. This report also includes new information on the significant risk for late-onset musculoskeletal complications. This is important because these complications have previously been shown to negatively affect a person's health status. 18 Even 35 years after the diagnosis, recurrent disease remains the most common cause of late mortality among ESSs. This is surprising because in the overall CCSS population, the cumulative incidence of nonrecurrence, nonexternal-cause late mortality eclipses that of recurrence 30 years after the diagnosis. 12 This result could be related to the fact that the number and types of effective chemotherapy agents available for ESSs treated between 1970 and 1986 were limited, and this resulted in fewer durable remissions. The introduction of ifosfamide and etoposide in the 1990s has improved outcomes for patients with localized Ewing sarcoma. 3 Thus, it is possible that the proportion of patients with late recurrence of disease will decrease among more recently treated patients. 3, 5 The incidence of SMNs also continued to rise among ESSs (cumulative incidence 35 years after the diagnosis, 14.3%). We previously reported a rate of 9% 25 years after the diagnosis. 15 The most frequent SMN was breast cancer among females. The Children's Oncology Group late-effect guidelines suggest early screening with mammography and magnetic resonance imaging for highrisk females, 25 and in light of the results presented here, this strategy may be warranted in this population. Although we were able to identify only chest radiotherapy as a treatment-related risk factor for SMNs, it will be important in the future to evaluate the impact of higher doses of alkylating agents 9, 26 and epipodophyllotoxins 27 on the cumulative incidence of SMNs because these agents have been reported to increase the risk of SNs 26, 28 and are used in more recent protocols for children with Ewing sarcoma.
On the basis of standard Ewing sarcoma therapy, it is not surprising that cardiac outcomes are a significant long-term complication related to the use of high doses of anthracyclines and radiotherapy. Cardiac complications result in significant morbidity 29, 30 and can affect the health of survivors and influence their activity level (an important factor in maintaining health). Our data show a significant dose-response association between cardiac outcomes and treatment with radiotherapy. This result is similar to the findings of previous CCSS reports for patients with Hodgkin lymphoma treated with mantle radiotherapy 31 and for the overall CCSS cohort. 32 Cardiac complications appear to increase from 15 to 30 years of follow-up without an apparent plateau, so it will be important to continue following these patients because cardiac complications will increase as the population ages.
In the current analysis, anthracyclines were not significantly associated with cardiac outcomes, but because of the small number of patients reported to have cardiac events (n 5 22) and the size of the anthracycline-treated Ewing cohort (n 5 306), this is likely related to low statistical power. Dexrazoxane administration decreases the early risk for subclinical disease in recently treated patients, 33 ,34 so long-term follow-up will be important for evaluating the impact of this strategy on long-term cardiac health. This is one of the first reports documenting the frequency of major surgical procedures for managing lateonset musculoskeletal complications (>5 years from the diagnosis) among long-term ESSs. Even after we account for original local-control surgical procedures, previous exposure to extremity radiation therapy is an important risk factor for future musculoskeletal complications. Although most complications occurred 5 to 15 years after the diagnosis; new events continued to appear even 30 years after the diagnosis. These findings expand on the results recently published by Stish et al 35 from a study of 79 patients treated for Ewing sarcoma at a single institution. These investigators reported that although many Ewing patients report excellent functional and quality-of-life outcomes, a significant number report long-term disability and impairment. An older age, female sex, and a pelvic tumor location identified their patients at greatest risk for longterm disability and impairment. One could speculate that the recent evolution of surgical techniques and improved internal prosthetic devices will result in a decrease in the number of patients needing amputations after the initial surgery and/or radiation. However, because limb-sparing surgery has become a more frequent therapeutic modality, [3] [4] [5] often combined with radiotherapy for microscopically positive margins, it will be important to compare our cohort's outcomes with more recently treated patients to determine the impact of combined surgery and radiation on long-term orthopedic sequelae among ESSs.
Our study has several limitations, including the selfreported nature of our outcomes. In addition, the cohort includes patients treated between 1970 and 1986; thus, the outcomes reported here may not be entirely applicable to current survivors because approximately 68% of the patients received radiotherapy and current treatment strategies attempt to limit the use of radiotherapy when feasible. The retrospective, self-reported nature of the surgical outcomes makes it challenging to draw concrete conclusions regarding surgical complications. Prospective data collection would more accurately help to group the various surgeries and the subsequent complications, especially because surgical techniques have evolved since this cohort study started. Furthermore, because joint replacements have limited lifespans, the revision of a prosthesis after it has completed its lifespan is very different from a revision due to an early complication (infection or mechanical failure). The time to failure and the type or extent of management required after failure are important details that should be included in any future analysis. That information will influence the conclusions regarding these outcomes. Furthermore, the evolution of surgical interventions and newer procedures may result in better functional outcomes even for patients who require surgery for treatment-related complications. Our report, however, should serve as a baseline against which future studies should compare outcomes for patients treated in more modern eras.
In conclusion, the evaluation of long-term outcomes in the Ewing sarcoma cohort followed by the CCSS after treatment between 1970 and 1986 confirms recurrent disease to be the most common cause of mortality. This cohort also had an increasing cumulative incidence of SMNs. ESSs are at risk for severe, disabling chronic health conditions, which increase over time and are related to treatment exposures. The continued need for aggressive multimodality therapy will continue to result in significant sequelae in these patients and in the continued need for long-term follow-up. The development and assessment of interventions designed to improve the long-term health of ESSs should be a priority.
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